Sarepta Therapeutics (SRPT) Rose To A 6-Week High After FDA Review Delayed

Sarepta Therapeutics (SRPT) announced Wednesday morning that it was notified by the FDA that it will be unable to complete its review of the new drug application for eteplirsen by the goal date of May 26.

from RTT - Before the Bell http://ift.tt/25nAclJ
via IFTTT